Biopharmaceutical Leader Francis Tavares Joins PreveCeutical Medical as Chief Technology Officer

Strategic Leadership Addition Strengthens Drug Discovery Capabilities

In a significant move within the health sciences sector, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has welcomed Dr. Francis Tavares to its executive ranks, effective June 27, 2025. The appointment of this seasoned pharmaceutical innovator as Chief Technology Officer represents a strategic enhancement to the company’s leadership structure as it pursues its ambitious agenda in preventive and curative therapy development.

Three Decades of Pharmaceutical Excellence

Dr. Tavares brings to the table an enviable track record spanning over 30 years in organic chemistry, medicinal chemistry, and drug discovery. Most recently, he served as President and CEO of ChemoGenics BioPharma, where he directed comprehensive drug discovery initiatives and championed the development of small molecule inhibitors targeting kinases, proteases, and nuclear receptors.

His accomplishments at ChemoGenics BioPharma include shepherding Trilaciclib through commercialization and overseeing Phase 3 clinical trials for Lerociclib, recognized as a best-in-class CDK4/6 inhibitor. Throughout his career, he has successfully managed over 15 metabolic targets and orchestrated multidisciplinary teams across medicinal chemistry, pharmacokinetics, and toxicology—consistently advancing drug candidates into clinical development stages.

Career Milestones and Academic Credentials

Dr. Tavares holds a PhD in Organic Chemistry from Colorado State University and completed postdoctoral studies at the University of Texas at Austin. His pharmaceutical journey includes a distinguished tenure at GlaxoSmithKline (GSK), where he held the position of Group Manager within the Medicinal Chemistry Division and received the Excellence in Science Award in 2004.

As founder of ChemoGenics BioPharma, Dr. Tavares established cutting-edge research facilities and cultivated strategic collaborations that supported multiple Phase I and II SBIR-funded initiatives, subsequently securing venture capital backing for product commercialization.

Vision for PreveCeutical’s Future

Stephen Van Deventer, Chairman and Chief Executive Officer of PreveCeutical, expressed enthusiasm about the appointment: “Dr. Tavares’s extensive background in translating scientific breakthroughs into market-ready solutions represents precisely the caliber of leadership our organization requires. His deep expertise in molecular drug design and his proven success in navigating complex clinical development pathways will be invaluable as we advance our portfolio of innovative therapies across multiple therapeutic areas.”

Dr. Tavares commented on his new role: “I am energized by the opportunity to drive technological innovation at PreveCeutical Medical, where groundbreaking science meets practical application in addressing critical unmet medical needs. I look forward to collaborating with the company’s exceptional team of researchers, physicians, and executives to develop therapeutic solutions that meaningfully impact patient outcomes. The organization’s vision and strategic direction present compelling opportunities for delivering next-generation treatments to market.”

PreveCeutical’s Research Portfolio

PreveCeutical operates as a health sciences company focused on developing innovative therapeutic options utilizing organic and nature-identical compounds. The organization currently maintains five active research and development initiatives: a dual gene therapy platform targeting diabetes and obesity prevention and treatment; the Sol-gel therapeutic program; Nature Identical™ peptide candidates for diverse medical applications; nonaddictive analgesic peptides engineered to provide alternatives to morphine, fentanyl, and oxycodone; and a specialized therapeutic intervention for concussion management in athletes experiencing mild traumatic brain injury.

The company aspires to establish itself as a preeminent force in preventive health sciences, with Francis Tavares’s appointment signaling an intensified commitment to accelerating product development timelines and expanding clinical validation efforts.

About PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences enterprise dedicated to advancing preventive and curative therapeutic solutions through nature-based and scientifically optimized formulations. For additional details, visit www.PreveCeutical.com or connect via Twitter and Facebook.

Contact Information

Stephen Van Deventer, Chairman & Chief Executive Officer Phone: (604) 306-9669 Email: info@PreveCeutical.com